Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading

British Journal of Pharmacology

Volumn 171, Issue 6, 2014, Pages 1501-1509

  Cavone, L ^a   Peruzzi, B ^b   Caporale, R ^b   Chiarugi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

dendritic cell; epitope spreading; PARP 1; RR EAE; Treg

Indexed keywords

6 PHENANTHRIDINONE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POLARITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; DRUG EFFICACY; EPITOPE SPREADING; EX VIVO STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMORAL IMMUNITY; IMMUNITY; IN VIVO STUDY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELAPSE; SHORT COURSE THERAPY;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; EPITOPES; MICE; OVALBUMIN; POLY(ADP-RIBOSE) POLYMERASES; RECURRENCE; T-LYMPHOCYTES, REGULATORY;

EID: 84895757281     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12525     Document Type: Article

References (35)

1. Aldinucci A, Gerlini G, Fossati S, Cipriani G, Ballerini C, Biagioli T, et al. (2007). A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J Immunol 179: 305-312. (Pubitemid 46986546)
2. Bailey SL, Schreiner B, McMahon EJ, Miller SD, (2007). CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 8: 172-180. (Pubitemid 46152648)
3. Banasik M, Komura H, Shimoyama M, Ueda K, (1992). Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267: 1569-1575.
4. von Boehmer H, Daniel C, (2013). Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 12: 51-63.
5. Cavone L, Chiarugi A, (2012). Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis? Trends Mol Med 18: 92-100.
6. Cavone L, Aldinucci A, Ballerini C, Biagioli T, Moroni F, Chiarugi A, (2011). PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult Scler 17: 794-807.
7. Chiarugi A, (2002a). Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br J Pharmacol 137: 761-770. (Pubitemid 35404175)
8. Chiarugi A, (2002b). PARP-1: killer or conspirator? The suicide hypothesis revisited. Trends Pharmacol Sci 23: 122-129.
9. Esposito M, Ruffini F, Bellone M, Gagliani N, Battaglia M, Martino G, et al. (2010). Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol 220: 52-63.
10. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL, (2009). Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10: 958-964.
11. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. (2007). Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851-862. (Pubitemid 47347319)
12. Jagtap P, Szabo C, (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440. (Pubitemid 40704125)
13. Kauppinen TM, Suh SW, Genain CP, Swanson RA, (2005). Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. J Neurosci Res 81: 190-198. (Pubitemid 41153332)
14. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
15. King SL, McNerney R, Withely GS, Johnstone AP, (1989). Differential role for ADP-ribosylation in gene expression during the activation of T lymphocytes by various stimuli. Immunology 67: 258-262. (Pubitemid 19151481)
16. Kraus WL, (2008). Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 20: 294-302.
17. Kraus WL, Lis JT, (2003). PARP goes transcription. Cell 113: 677-683. (Pubitemid 36724932)
18. Krishnakumar R, Kraus WL, (2010). The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39: 8-24.
19. Lutz MB, Schuler G, (2002). Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23: 445-449. (Pubitemid 35015188)
20. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
21. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD, (2005). Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11: 335-339. (Pubitemid 40460563)
22. McNerney R, Tavasolli M, Shall S, Brazinski A, Johnstone AP, (2001). Changes of mRNA levels of poly(ADP-ribose) polymerase during activation of human lymphocytes. Biochim Biophys Acta 1009: 185-187.
23. Manicassamy S, Pulendran B, (2011). Dendritic cell control of tolerogenic responses. Immunol Rev 241: 206-227.
24. Nasta F, Laudisi F, Sambucci M, Rosado MM, Pioli C, (2010). Increased Foxp3+ regulatory T cells in poly(ADP-ribose) polymerase-1 deficiency. J Immunol 184: 3470-3477.
25. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al.(2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U.S.A 105: 17079-17084.
26. Rutella S, Lemoli RM, (2004). Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett 94: 11-26. (Pubitemid 38953707)
27. Scott GS, Hake P, Kean RB, Virag L, Szabo C, Hooper DC, (2001). Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J Neuroimmunol 117: 78-86. (Pubitemid 32595495)
28. Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley JG, Szabo C, et al. (2004). The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl) -N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther 310: 1053-1061. (Pubitemid 39108927)
29. Tisch R, (2010). Immunogenic versus tolerogenic dendritic cells: a matter of maturation. Int Rev Immunol 29: 111-118.
30. Tuohy VK, Kinkel RP, (2000). Epitope spreading: a mechanism for progression of autoimmune disease. Arch Immunol Ther Exp (Warsz) 48: 347-351.
31. Vanderlugt CL, Miller SD, (2002). Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2: 85-95. (Pubitemid 37323232)
32. Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, et al. (1998). The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 164: 63-72. (Pubitemid 28438396)
33. Weltin D, Picard K, Aupeix K, Varin M, Oth D, Marchal J, et al. (1995). Immunosuppressive activities of 6(5)-phenanthridinone, a new poly(ADP-ribose) polymerase inhibitor. Int J Immunopharmacol 17: 265-271.
34. Yap TA, Sandhu SK, Carden CP, de Bono JS, (2011). Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61: 31-49.
35. Zhang P, Maruyama T, Konkel JE, Abbatiello B, Zamarron B, Wang ZQ, et al. (2013). PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PLoS ONE 8: e71590.